<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B358D146-50FA-41DE-A7A9-AA30193D6A21"><gtr:id>B358D146-50FA-41DE-A7A9-AA30193D6A21</gtr:id><gtr:name>Intervet-Schering Plough</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/01D58A80-A729-4F08-B0FF-03C1B2622320"><gtr:id>01D58A80-A729-4F08-B0FF-03C1B2622320</gtr:id><gtr:name>Moredun Research Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Sch of Biological Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B358D146-50FA-41DE-A7A9-AA30193D6A21"><gtr:id>B358D146-50FA-41DE-A7A9-AA30193D6A21</gtr:id><gtr:name>Intervet-Schering Plough</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/01D58A80-A729-4F08-B0FF-03C1B2622320"><gtr:id>01D58A80-A729-4F08-B0FF-03C1B2622320</gtr:id><gtr:name>Moredun Research Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/11FFBE61-38FF-4365-B910-2FE02113BB27"><gtr:id>11FFBE61-38FF-4365-B910-2FE02113BB27</gtr:id><gtr:firstName>Keith</gtr:firstName><gtr:otherNames>Roland</gtr:otherNames><gtr:surname>Matthews</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FL02442X%2F1"><gtr:id>CF6A1F23-F477-4FF3-9ADA-C3F77BF4277D</gtr:id><gtr:title>Technical development of a novel vaccine vehicle for cattle pathogens</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L02442X/1</gtr:grantReference><gtr:abstractText>Trypanosoma theileri is a ubiquitous single celled organism present in cattle herds worldwide. Using knowledge of gene expression and protein trafficking in other trypanosomatid organisms, we have successfully developed T. theileri as a delivery system for vaccine antigens and therapeutics. Following recommendations from several Animal Health companies, we now aim to develop and demonstrate the potential of T. theileri as an effective and practical vaccine-vehicle, providing a clear route to commercialisation.

In a two-step development path, Phase 1 will focus on technical refinements and analysis of the viability of the vaccine-vehicle during storage and distribution. The flexibility of the system to express antigens from a range of pathogens will also be established. Phase 2 will entail confirmation of the in vivo efficacy of the refinements developed in Phase 1.

Combined the experiments will address key hurdles to the commercial development of this patented vaccine system.</gtr:abstractText><gtr:fund><gtr:end>2017-04-21</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-10-27</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>305155</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Moredun Research Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaboration with Moredun</gtr:description><gtr:id>2AC3ECDE-E34C-4530-9E84-679AE87E508B</gtr:id><gtr:impact>See publication linked to this output</gtr:impact><gtr:partnerContribution>Provision of a contained cattle facility</gtr:partnerContribution><gtr:piContribution>Provision of transgenic T theileri for the infection of cattle in a contained facility to evaluate immune responses generated toe expressed antigens</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intervet-Schering Plough</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Intervet collaboration</gtr:description><gtr:id>0930B85C-D810-422F-92A1-05A714AA957F</gtr:id><gtr:impact>Publication
Mott, G. A.; Wilson, R.; Fernando, A.; Robinson, A.; MacGregor, P.; Kennedy, D.; Schaap, D.; Matthews, J. B. and Matthews, K. R. (2011) Targetting cattle-borne zoonoses and cattle pathogens using a novel trypanosomatid-based delivery system. PLoS Pathogens, 7(10):e1002340.

Outreach
Wellcome Trust blog: http://blog.wellcome.ac.uk/2012/02/14/neglected-tropical-diseases-working-with-animals/
BBSRC news feature: http://www.bbsrc.ac.uk/news/food-security/2011/111028-pr-cattle-parasite-vaccine.aspx
Veterinary record news report: http://veterinaryrecord.bmj.com/content/169/21/541.1.extract</gtr:impact><gtr:partnerContribution>Intervet provided technical guidance, reagents and IP protection support. They also provided a cash contribution to the award as required by the Industrial Partnership scheme.</gtr:partnerContribution><gtr:piContribution>We evaluated a novel vaccine vehicle for the delivery of antigens to cattle. We expressed an antigen provided by Intervet (after expression optimisation of the vaccine delivery vehicle) and tested its immunogenicity in cattle.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>334000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Innovate UK</gtr:department><gtr:description>SBRI Vaccines for Global Epidemics - Preclinical Stage 1</gtr:description><gtr:end>2018-04-02</gtr:end><gtr:fundingOrg>Government of the UK</gtr:fundingOrg><gtr:fundingRef>86235-544135</gtr:fundingRef><gtr:id>8BAD47B8-D3C9-4295-98E1-9F9192A54880</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>117261</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GCRF Challenge award</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:fundingRef>CH160034</gtr:fundingRef><gtr:id>48A1324F-1D4A-4DB1-B047-B283EEEF5877</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The work has been progressed to European patent filing, and this was granted in early 2017</gtr:description><gtr:firstYearOfImpact>2017</gtr:firstYearOfImpact><gtr:id>B1917885-A7DC-4584-9F9F-EE00A0C4A685</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Agriculture, Food and Drink</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We developed Trypanosome theileri as a vaccine vehicle for the delivery of antigens and other therapeutics to cattle</gtr:description><gtr:id>DD95A532-A7E7-4285-BF08-CB0CF4ED959B</gtr:id><gtr:impact>The patent application is under review in the US at present. Development work is being supported by a BBBSRC Super Follow on fund application</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>EP10171304.8</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>'Recombinant Trypanosoma theileri parasite'</gtr:title></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>This project has started as of October 2014. The experiments are currently ongoing but have, to date, demonstrated the ability of Trypanosoma theileri to express heterologous antigens from episomal vectors. Many constructs to optimise the system and ensure containment have been developed and will soon be used in vivo to test their antigen delivery. Finally, we have explored the cold chain stability of Trypanosoma theileri and have generated robust and key data required by industry to assess the practical application of our novel delivery vehicle.

In 2016/2017 we were able to demonstrate the longevity of Episomal expression within the vaccine vehicle and carried out in vivo trials using episomal expression vectors, as well as integrative expression vectors in an auxotrophic mutant. The immunogenicity of the new vehicles is currently being analysed and compared with earlier studies.</gtr:description><gtr:exploitationPathways>Our research programme aims to evaluate and develop a novel system for the sustained delivery of an unlimited range of pathogen antigens specific to cattle. Being defined and characterised in terms of their immunogenicity, vaccinated and diseased animals are able to be identified and distinguished. Moreover, the technology proposed has economic advantages over the existing expensive and labour-intensive production of attenuated vaccines. This offers clear advantages to the agricultural and animal healthcare industry at large.

 The proposal will develop early-stage work, with substantial commitment from an Industrial Partner, to demonstrate utility and provide the required scientific validation to stimulate further development in an industrial setting with the partner company.

The proposal fulfils the strategic remit of the animal sciences panel with respect to: 
 
The 'control of infectious diseases', (priority area) comprising 'identification of protective antigens', 'vaccinology' and 'improved antigen delivery systems'. Strategic plan objectives for 'Sustainable Agriculture' comprise 'host/pathogen interactions', 'animal welfare' and the 'control of animal diseases'.

In 2016/2017 we successfully secured further funding based on the concepts developed in this proposal. One grant was for development of an equivalent vaccination system using sheep trypanosomatids (Royal Society Challenge award). Another was to explore the viability of the current system to vaccinate against major zoonotic infections that pose risk for human epidemics (Innovate UK)</gtr:exploitationPathways><gtr:id>E41A2693-CF00-40FD-A9E1-36D7CF355C40</gtr:id><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Education,Manufacturing, including Industrial Biotechology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/L02442X/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>